
    
      200 patients that are candidates for intravesical BCG therapy and 20 control patients with no
      history of malignancy will be enrolled. The study group wol;; be asked to provide a urine
      sample just prior to receiving their first BCG treatment(week # 1) and just prior to
      receiving their last (week # 6) BCG treatment. The control patients will provide one urine
      sample only. Samples will be analysed by enzyme-linked immunosorbant assay(ELISA). clinical
      data will be reviewed on tumor stage and grade prior to BCG, timme to recurrence, tumor stage
      and grade of recurrence, time to disease progression and death, cause of death and total
      follow-up time.
    
  